Reproterol is a short-acting[1] β2 adrenoreceptor agonist used in the treatment of asthma.[2]

It was patented in 1965 and came into medical use in 1977.[3]

Stereochemistry

Reproterol contains a stereocenter and is chiral. There are thus two enantiomers, the (R)-form and the (S)-form. The commercial preparations contain the drug as a racemate, an equal mixture of the two enantiomers.[4]

Enantiomers of reproterol

(R)-Reproterol
CAS number: 210710-33-1
(S)-Reproterol
CAS number: 210710-34-2

References

  1. ^ Küpper T, Goebbels K, Kennes LN, Netzer NC (December 2012). "Cromoglycate, reproterol, or both--what's best for exercise-induced asthma?". Sleep & Breathing = Schlaf & Atmung. 16 (4): 1229–35. doi:10.1007/s11325-011-0638-2. PMID 22198635. S2CID 10032756.
  2. ^ Virchow JC (1999). "Reproterol: beta-2-agonist, theophylline, or both?". Respiration; International Review of Thoracic Diseases. 66 (3): 210–1. doi:10.1159/000029379. PMID 10364735. S2CID 203732706.
  3. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 54X. ISBN 9783527607495.
  4. ^ Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Vol. 57. Frankfurt/Main: Rote Liste Service GmbH. 2017. p. 196. ISBN 978-3-946057-10-9.